The present study examined whether the strength capability of knee extensor muscles is associated with global cognitive function, assessed by Mini-Mental State Examination (MMSE), in non-disabled elderly men. Isometric torques during maximal voluntary knee extension, plantar flexion, and elbow flexion and MMSE scores were determined in 39 non-disabled men aged 61-79 years and used for the cross-sectional analysis examining the associations among the measured variables. Moreover, 27 of the subjects participated in a training program consisted of body mass-based exercises (sitting down onto and standing up from a chair, hip joint extension and flexion, calf raises, side leg raises, and trunk flexion and extension) 6 days a week for 3 months. Isometric torques and MMSE scores were determined after the intervention. Among the data before intervention, only knee extension torque (KET) and KET relative to body mass (KET/BM) significantly correlated to the MMSE scores: r = 0.579 (P < 0.0001) for KET and r = 0.520 (P < 0.001) for KET/BM. After the intervention, KET and KET/BM increased significantly, but MMSE score did not. However, the absolute change in MMSE scores was significantly associated with that in KET (r = 0.381, P < 0.05) and KET/BM (r = 0.422, P < 0.05). These findings indicate that the strength capability of knee extensors is associated with global cognitive function in non-disabled elderly men, and provide a new perspective to a general concept that exercises strengthening knee extensor muscles should be included in resistance training programs for elderly individuals.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00421-011-2176-9DOI Listing

Publication Analysis

Top Keywords

mmse scores
16
knee extensor
12
elderly men
12
mini-mental state
8
state examination
8
strength capability
8
capability knee
8
extensor muscles
8
associated global
8
global cognitive
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Cognition Therapeutics, Purchase, NY, USA.

Background: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.

Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

EQT Life Sciences Partners, Amsterdam, 1071 DV Amsterdam, Netherlands.

Background: Alzheimer's disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility criteria. Here, we report the main reasons for screening failure in the 12-week screening phase of the ongoing evoke (NCT04777396) and evoke+ (NCT04777409) trials of semaglutide in early AD.

Method: Key inclusion criteria were age 55-85 years; mild cognitive impairment due to AD (Clinical Dementia Rating [CDR] global score of 0.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: The Mini-Mental State Examination (MMSE) is a common screening tool in Alzheimer's disease (AD) clinical trials. MMSE score inflation at inclusionary visits poses challenges by potentially amplifying placebo responses and complicating the detection of treatment effects. Despite these concerns, prior research (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!